These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10087004)

  • 1. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
    J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.
    Jiménez W; Gal CS; Ros J; Cano C; Cejudo P; Morales-Ruiz M; Arroyo V; Pascal M; Rivera F; Maffrand JP; Rodés J
    J Pharmacol Exp Ther; 2000 Oct; 295(1):83-90. PubMed ID: 10991964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention.
    Ros J; Fernández-Varo G; Muñoz-Luque J; Arroyo V; Rodés J; Gunnet JW; Demarest KT; Jiménez W
    Br J Pharmacol; 2005 Nov; 146(5):654-61. PubMed ID: 16113688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs.
    Brooks DP; Valente M; Petrone G; Depalma PD; Sbacchi M; Clarke GD
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1176-83. PubMed ID: 9067301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Jiménez W; Angeli P; Leivas A; Clària J; Graziotto A; Arroyo V; Rivera F; Rodés J
    Gastroenterology; 1995 Jul; 109(1):217-23. PubMed ID: 7797019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers.
    Bellissant E; Denolle T; Sinnassamy P; Bichet DG; Giudicelli JF; Lecoz F; Gandon JM; Allain H
    J Pharmacol Exp Ther; 1996 Jul; 278(1):232-42. PubMed ID: 8764356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis.
    Moreau R; Cailmail S; Hamon G; Lebrec D
    J Gastroenterol Hepatol; 1996 Sep; 11(9):857-63. PubMed ID: 8889966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
    Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
    J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aquaretic agents].
    Jiménez W
    Nefrologia; 2002; 22 Suppl 5():52-5. PubMed ID: 12107918
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
    Hirano T; Yamamura Y; Nakamura S; Onogawa T; Mori T
    J Pharmacol Exp Ther; 2000 Jan; 292(1):288-94. PubMed ID: 10604960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
    Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
    Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
    Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
    Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis.
    Gadano A; Moreau R; Pessione F; Trombino C; Giuily N; Sinnassamy P; Valla D; Lebrec D
    J Hepatol; 2000 Jan; 32(1):38-42. PubMed ID: 10673065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
    Takeuchi M; Lee JD; Shimizu H; Ueda T
    Int J Cardiol; 2006 Apr; 108(2):231-6. PubMed ID: 16002161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
    Ohnishi A; Orita Y; Takagi N; Fujita T; Toyoki T; Ihara Y; Yamamura Y; Inoue T; Tanaka T
    J Pharmacol Exp Ther; 1995 Feb; 272(2):546-51. PubMed ID: 7853167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aquaretic agents].
    Bosch-Marcé M; Clària J; Jiménez W
    Gastroenterol Hepatol; 1996 Nov; 19(9):472-7. PubMed ID: 8998673
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.
    Fernández-Varo G; Ros J; Cejudo-Martín P; Cano C; Arroyo V; Rivera F; Rodés J; Jiménez W
    J Hepatol; 2003 Jun; 38(6):755-61. PubMed ID: 12763368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.